Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Expert interview - 08/03/2023 Portrait photo of an older man with glasses and grey hair in a suit.

    How do new active substances from university research reach patients?

    Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-do-new-active-substances-university-research-reach-patients
  • Press release - 29/11/2022

    Prototype funding for two Konstanz projects

    Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/doppelter-erfolg-der-prototypenfoerderung
  • Press release - 12/04/2022

    Technology transfer award for PCR rapid test device for infection diagnostics

    Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-transfer-award-pcr-rapid-test-device-infection-diagnostics
  • Press release - 10/03/2022

    Innovation Day Upper Rhine provides cross-border knowledge transfer

    Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
  • Press release - 26/05/2021

    Memetis continues its path to become a technology leader in Shape Memory driven miniature valving – Fluid-o-Tech S.r.l. invests an undisclosed amount to support memetis’ growth and development

    The Deep-Tech Start-Up memetis GmbH from Germany, which produces the world’s most compact and lightest commercially available valves driven by shape memory alloys, announces a new partnership with Fluid-o-Tech S.r.l., an Italian innovation and market leader in the field of fluid-pumps.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/memetis-continues-its-path-become-technology-leader-shape-memory-driven-miniature-valving-fluid-o-tech-srl-invests-undisclosed-a
  • Press release - 13/04/2021

    Evotec’s BRIDGE “beLAB2122” leverages academic innovation from our region

    Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/evotecs-bridge-belab2122-leverages-academic-innovation-our-region
  • Press release - 04/03/2021

    CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-novartis-sign-initial-agreement-manufacturing-covid-19-vaccine-candidate-cvncov
  • Company profile - 16/12/2019 Ausschnitt aus dem Mikrofluidik-System von Velabs, das dicht gepackt ist mit einzelnen Tröpfchen

    Velabs Therapeutics GmbH: each droplet is a test system

    Using microfluidics to detect new therapeutic antibodies is, in simple terms, the concept developed by Velabs Therapeutics GmbH. The Heidelberg-based start-up was spun out from the European Molecular Biology Laboratory (EMBL) in 2017 with the support of EMBLEM Technology Transfer GmbH. More recently, investors have provided the young company with additional funding to expand its technologies and applications.

    https://www.gesundheitsindustrie-bw.de/en/article/news/velabs-therapeutics-gmbh-each-droplet-test-system
  • Press release - 27/06/2019

    Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme

    Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/velabs-therapeutics-announces-eur3-million-series-b-financing-advance-its-functional-antibody-screening-programme
  • Article - 15/01/2018 Schematic showing how a blockchain works.

    Blockchain technology as an opportunity for more transparency and self-determination

    In the healthcare sector, blockchain technology is still in the early stages of development, although it has huge potential in this field. It is expected that patients will particularly benefit from the introduction of a decentralised database for managing and sharing health-related information with treating physicians. Statutory health insurance companies become less important as intermediaries. But how exactly does this technology work?

    https://www.gesundheitsindustrie-bw.de/en/article/news/blockchain-technology-as-an-opportunity-for-more-transparency-and-self-determination
  • Article - 24/07/2017 The figure shows a model of the IDH1 complex. Two polypeptide chains (brown and light blue) form a dimer between which the substance BAY 1436032 (yellow) binds.

    Cancer medicine development as a science and industry partnership

    The German Cancer Research Center (DKFZ) and Bayer AG are collaborating on a strategic partnership focusing on the development of innovative cancer therapies. The two partners have developed an active substance which selectively blocks a mutation of a metabolic enzyme that occurs in certain types of cancer. The substance has been successfully tested in preclinical studies and is now also being tested in a clinical trial on patients with brain…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-medicine-development-as-a-science-and-industry-partnership
  • Article - 01/06/2017 Woman in a blue lab coat pipetting a blue liquid into an electrophoresis system.

    Biotechnology – key technology of the 21st century

    According to a study published by the German National Academy of Science and Engineering (acatech) on 5th April, biotechnology is a key technology of the 21st century and has huge innovation potential. What are the trends within the industry and what are the challenges we face?

    https://www.gesundheitsindustrie-bw.de/en/article/news/biotechnology-key-technology-of-the-21st-century
  • Article - 19/04/2017 View of a laboratory work place with a broad range of laboratory utensils in which a person (on the left, wearing a white lab coat) is working with frozen samples.

    Are start-ups a matter for the boss? A professor’s thoughts on university spin-offs

    Research work and entrepreneurship are by no means mutually exclusive. There are numerous successful university spin-offs in the life sciences sector that prove this only too well. However, the road from a good idea to a commercially successful company can be long and arduous. Those who benefit from the support of their boss from the outset can consider themselves extremely fortunate. Prof. Dr. Hans-Georg Rammensee talks about his experience with…

    https://www.gesundheitsindustrie-bw.de/en/article/news/are-start-ups-a-matter-for-the-boss-a-professors-thoughts-on-university-spin-offs
  • Press release - 24/01/2017

    Cancer Medications Learn to Hide

    The European Research Council awards Wilfried Weber an ERC Proof of Concept Grant. Wilfried Weber, Professor of Synthetic Biology at the University of Freiburg, has received a grant of roughly €150,000 for his project “Hide and Seek with Cancer Drugs” in which he is working to improve the drugs used in cancer treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-medications-learn-to-hide
  • Press release - 13/12/2016 A laboratory device being loaded with small reaction vessels.

    Early-diagnosis systems from Baden-Württemberg help prevent the spread of drug-resistant pathogens

    More and more bacteria are developing resistance to multiple antimicrobial drugs. These multidrug-resistant bacteria can impede the action of common antibiotics via mutations or DNA transfer. More than 30,000 people are infected every year with multidrug-resistant bacteria in German hospitals alone. This could be prevented with appropriate hygiene measures and innovative test systems. Innovative test systems that enable reliable and rapid…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fruehdiagnostik-aus-baden-wuerttemberg-hilft-resistente-erreger-zu-stoppen
  • Article - 06/06/2016 Labbild_4.jpg

    ZEISS Vision Science Lab: understanding vision

    Carl Zeiss AG and the University of Tübingen have been jointly running the ZEISS Vision Science Lab since 2013. This is a workgroup that is both fully integrated into research as well as delivering results for the development and improvement of products. The “Industry on Campus” professorship shows how different interests can turn out successfully for both parties involved.

    https://www.gesundheitsindustrie-bw.de/en/article/news/zeiss-vision-science-lab-understanding-vision
  • Medical technology - 14/03/2016 Experimenteller_Interventionsraum_mit_mobilen_Rontgengerat_Monitoren_und_OP-Tisch_an_dem_der_Interventionsassistent_herangefahren_werden_kann.jpg

    The operating room of the future: minimally invasive and future-oriented intervention techniques

    Being able to diagnose and treat tumour patients in just a few hours is just one of the many promising goals of the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB). The overall goal of the Intervention and Therapy research group is to take innovative technologies for diagnostic and therapeutic interventions from laboratory development to prototype production for use in clinical trials.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-operating-room-of-the-future-minimally-invasive-and-future-oriented-intervention-techniques
  • The Baden-Württemberg healthcare industry

    Infrastructure

    Baden-Württemberg is home to numerous technology parks and thus offers an excellent infrastructure and attractive high-tech locations for life sciences companies in close proximity to scientific excellence. Young companies and business start-ups particularly stand to benefit from the opportunities for cooperation with other companies and research institutions in the technology parks and also from the relatively cheap rents for office and…

    https://www.gesundheitsindustrie-bw.de/en/location/infrastructure
  • Press release - 03/08/2012 09262_de.jpg

    Rentschler and MHH sign licensing agreement for a gene therapy vector system

    The Hannover Medical School (MHH) and Rentschler Biotechnologie GmbH have signed a licensing agreement for the commercialization of a vector system for gene therapy that promises significant therapeutic and economic advantages over conventional technologies. Rentschler, an experienced specialist in the development of cell culture-based manufacturing processes and the production of relevant biopharmaceuticals, attains the right to develop…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-and-mhh-sign-licensing-agreement-for-a-gene-therapy-vector-system
  • Press release - 12/07/2012

    7. Framework Programme: aid for organizations and companies

    The last round of file ideas for projects within the 7th Research framework program has been started. The European Commission will support innovative projects over eight billion euros to europe for global competition to strengthen and protect jobs. In addition to innovation, the focus is on health, environment, urbanization and waste disposal. The promotion is organizations and companies in all EU-member-states and partner countries open.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/7-framework-programme-aid-for-organizations-and-companies
  • Press release - 05/12/2011 10163_de.JPG

    Cellzome founder wins EU women innovators award

    Cellzome announces 5 December 2011 that Dr. Gitte Neubauer has received the highly esteemed EU Women Innovators Award. The award recognizes her outstanding contribution in translating academic research into a commercial venture through the foundation of Cellzome. The prize value of 100.000 euros awarded by the European Commission Innovation Union was presented by Jos Manuel Barroso in a ceremony as part of the Innovation Convention 2011 in…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellzome-founder-wins-eu-women-innovators-award
  • Press release - 16/09/2011

    Five countries and EMBL sign Memorandum of Understanding to make ELIXIR a reality

    Today marks an important step for ELIXIR, Europe’s emerging research infrastructure for life-science information, as five countries plus the European Molecular Biology Laboratory (EMBL) have signed a Memorandum of Understanding to catalyse the implementation and construction of ELIXIR. The memorandum has been signed by Denmark, Finland, the Netherlands, Sweden and the United Kingdom, and more countries are planning to join in the near future. All…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-countries-and-embl-sign-memorandum-of-understanding-to-make-elixir-a-reality
  • Press release - 02/09/2011 15267_de.jpg

    German Government starts the initiative "Health - Made in Germany"

    The overall aim of the initiative is to exploit the dormant capacities that lie within the export of health care products made in Germany. In Germany, many companies are already world leaders in their fields, in part due to a policy of consistent and early promotion of health care in Germany. German technology suppliers possess decades of valuable experience in realizing health care projects both at home and abroad. Provider of products and…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-government-starts-the-initiative-health-made-in-germany
  • Press release - 27/06/2011 14614_de.jpg

    NMI TT GmbH – creating value from research

    NMI TT GmbH is a subsidiary of the NMI Natural and Medical Sciences Institute in Reutlingen with which it works closely. Developments by the renowned NMI are commercialised by NMI TT GmbH and the profit flows back into the NMI’s research activities – thus leading to a value creation cycle that benefits research and development as well as the economy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-gmbh-creating-value-from-research
  • Article - 06/06/2011 Professor Gunter Voigt lectures and researches at HTWG Konstanz

    Knowledge transfer depends on the application of learning

    The ability of scientists from different disciplines to understand each other as well as excellent communication skills play an ever-increasing role in the transfer of knowledge from academic research to industry. Vice president of research at the Konstanz University of Applied Sciences HTWG Professor Gunter Voigt explains how academia and industry work together and also highlights the conditions that are necessary for such cooperations to lead…

    https://www.gesundheitsindustrie-bw.de/en/article/news/knowledge-transfer-depends-on-the-application-of-learning

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search